Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

61. Clinicopathological significance of Ki67 expression in colorectal cancer: a protocol of systematic review and meta-analysis Full Text available with Trip Pro

Clinicopathological significance of Ki67 expression in colorectal cancer: a protocol of systematic review and meta-analysis Inplasy Protocol 09 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

62. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europ

leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GI cancers. The most prevalent digestive cancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma (...) Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europ Position Statement Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Societyof Gastrointestinal Endoscopy (ESGE) Position Statement Authors AdrianSaftoiu 1,2 ,CesareHassan 3 ,MiguelAreia 4,5 ,ManoopS. Bhutani 6 ,RafBisschops 7 ,ErwanBories 8 ,IrinaM. Cazacu 1,6 ,EvelienDekker 9 , PierreH.Deprez 10 ,StephenP.Pereira 11 ,CarloSenore 12 ,RiccardoCapocaccia 13

2020 European Society of Gastrointestinal Endoscopy

63. Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery Full Text available with Trip Pro

surgery for colorectal cancer were divided randomly into three groups: combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group). The primary endpoint was duration of hospital stay. Secondary endpoints included gastrointestinal motility, pain scores and plasma levels of cytokines.In total, 180 patients were randomized and 165 completed the trial. The intention-to-treat analysis showed that duration of hospital (...) Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery The optimal analgesia regimen after laparoscopic colorectal cancer surgery is unclear. The aim of the study was to characterize the beneficial effects of continuous transversus abdominis plane (TAP) blocks initiated before operation on outcomes following laparoscopic colorectal cancer surgery.Patients undergoing

2020 EvidenceUpdates

64. Incidence of Incisional Hernia Repair After Laparoscopic Compared to Open Resection of Colonic Cancer: A Nationwide Analysis of 17,717 Patients (Abstract)

comprised of patients undergoing resection for colonic cancer between January 2007 and March 2016 according to the Danish Colorectal Cancer Group database. Patients who subsequently underwent IHR were identified in the Danish Ventral Hernia Database, from which information about the priority of the hernia repair and the size of the fascial defect was retrieved.The study included 17,717 patients, of whom 482 (2.7%) underwent subsequent IHR during a median follow-up of 4.7 (interquartile range 2.8-6.9 (...) Incidence of Incisional Hernia Repair After Laparoscopic Compared to Open Resection of Colonic Cancer: A Nationwide Analysis of 17,717 Patients It remains unknown whether laparoscopic compared to open surgery translates into fewer incisional hernia repairs (IHR). The objectives of the current study were to compare the long-term incidence of IHR and the size of repaired hernias between patients subjected to laparoscopic or open resection of colonic cancer.This was a nationwide cohort study

2020 EvidenceUpdates

65. AB050. Transverse versus extended colectomy for transverse colon cancer: a systematic review and meta-analysis Full Text available with Trip Pro

for transverse colon cancer: a systematic review and meta-analysis Session 3: Colorectal AB050. Transverse versus extended colectomy for transverse colon cancer: a systematic review and meta-analysis Stefan Morarasu, Helen Heneghan, Cillian Clancy, Desmond Winter Download Citation Share About AME Publishing Company Copyright © 2009 - 2021 AME Publishing Company. All rights reserved. Published by AME Publishing Company Address: Rm C, 16/F, Kings Wing Plaza 1, No. 3 On Kwan Street, Shatin, NT, Hong Kong Email: (...) AB050. Transverse versus extended colectomy for transverse colon cancer: a systematic review and meta-analysis AB050. Transverse versus extended colectomy for transverse colon cancer: a systematic review and meta-analysis - Morarasu - Mesentery and Peritoneum Have a website account? or for exclusive website content. Title Full Text Author / / AB050. Transverse versus extended colectomy for transverse colon cancer: a systematic review and meta-analysis AB050. Transverse versus extended colectomy

2020 Mesentery and Peritoneum

66. Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis Full Text available with Trip Pro

had a better overall survival and a better disease-free survival. The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery. Citation: Fu HT, Xu YY, Tian JJ, Fu JX, Nie SL, Tang YY, Chen P, Zong L. Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis. World J Meta-Anal 2020; 8(1): 27-40 URL: DOI: INTRODUCTION Colorectal cancer (CRC) accounts for 9% of all cancers worldwide. It is the second most (...) , the XELOX regimen is recommended for stage III colon cancer after surgery. ARTICLE HIGHLIGHTS Research background Colorectal cancer (CRC) accounts for 9% of all cancers in the world. In the last decade, it is the third most common malignant tumor in Europe and the United States. There is an urgent need to establish an effective standard treatment for CRC. In addition, more than 70% of CRC-related deaths are associated with the liver metastasis. A recurrence rate and poor overall survival make CRC

2020 World journal of meta-analysis

67. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 4. 2 or 3 5. 1 and 4 6. colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate/) 7. mammography/ or mammogra*.ti,ab. 8. (colonography or colonoscop* or fobt or sigmoidoscop*).ti,ab (...) EK, Nguyen TT, Lo P, et al. Lay health educators increase colorectal cancer screening among Hmong Americans: a cluster randomized controlled trial. Cancer 2017;123(1):98-106. Walsh JM, Salazar R, Nguyen TT, et al. Healthy colon, healthy life: a novel colorectal cancer screening intervention. American Journal of Preventive Medicine 2010;39(1):1-14. Wang X, Fang C, Tan Y, Liu A, Ma GX. Evidence-based intervention to reduce access barriers to cervical cancer screening among underserved Chinese

2020 Community Preventive Services Task Force

68. Colorectal cancer

with early rectal cancer 23 Preoperative treatment for people with rectal cancer 24 Surgery for people with rectal cancer 26 Surgical technique for people with rectal cancer 27 People with locally advanced or recurrent rectal cancer 28 Surgical volumes for rectal cancer operations 29 Preoperative treatment for people with colon cancer 30 Duration of adjuvant chemotherapy for people with colorectal cancer 30 Colonic stents in acute large bowel obstruction 32 Molecular biomarkers to guide systemic anti (...) , and pT4 and/or pN2), performance status, any comorbidities, age and personal preferences. T o find out why the committee made the recommendation on duration of adjuvant chemotherapy for people with colorectal cancer and how it might affect practice, see rationale and impact. Colonic stents in acute large bowel obstruction Colonic stents in acute large bowel obstruction 1.3.15 Consider stenting for people presenting with acute left-sided large bowel obstruction who are to be treated with palliative

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

69. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Full Text available with Trip Pro

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Improved markers of prognosis are needed to stratify patients with early-stage colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to develop a biomarker of patient outcome after primary colorectal cancer resection by directly analysing scanned conventional haematoxylin and eosin stained sections using deep learning.More than 12 000 000 image tiles from patients (...) prepared in Norway. All cohorts included only patients with resectable tumours, and a formalin-fixed, paraffin-embedded tumour tissue block available for analysis. The primary outcome was cancer-specific survival.828 patients from four cohorts had a distinct outcome and were used as a training cohort to obtain clear ground truth. 1645 patients had a non-distinct outcome and were used for tuning. The biomarker provided a hazard ratio for poor versus good prognosis of 3·84 (95% CI 2·72-5·43; p<0·0001

2020 Lancet

70. Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials Full Text available with Trip Pro

Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research (...) Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials Shan Xu, Ali Sak, Yasin Bahadir Erol Shan Xu Universitat

2020 Research Square

71. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. (Abstract)

Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance paradigms, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account, such as by assessing CRC incidence by tumour stage, or stage-adjusted mortality from CRC. We aimed to compare both overall and country-specific risks of CRC (...) Classification of Disease in the patient register (in the country in question) or one such record plus a colorectal biopsy report with a morphology code suggestive of inflammatory bowel disease. For every patient with UC, we selected matched reference individuals from the total population registers of Denmark and Sweden, who were matched for sex, age, birth year, and place of residence. We used Cox regression to compute hazard ratios (HRs) for incident CRC, and for CRC mortality, taking tumour stage

2020 Lancet

72. KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square (...) does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis Iraj Shahramian, Fateme Parooie, morteza salarzaei Iraj Shahramian

2020 Research Square

73. Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Full Text available with Trip Pro

Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting (...) preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis Juli Lin, Jian-xian Lin, Chao-hui Zheng, Ping Li, Jian-wei Xie, Jia-bin Wang, Jun Lu, Qi-yue Chen, Long-Long Cao, Mi Lin, Chang-ming Huang Juli Lin Xiehe Affiliated Hospital

2020 Research Square

74. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

cancer mortality in first- degree relatives ofearly-onset colorectal cancer cases. Dis Colon Rectum 2002; 45: 681–686 [107] Kune GA, Kune S, Watson LF. The role of heredity in the etiologyof large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13: 124–129 ; discussion 9–31 [108] Samadder NJ, Smith KR, Hanson H et al. Increased riskofcolorectal canceramongfamilymembersofallages,regardlessofageofindex case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311 (...) : 78–85 [3] JaspersonKW,TuohyTM,NeklasonDWetal.Hereditaryandfamilial colon cancer. Gastroenterology 2010; 138: 2044–2058 [4] Hampel H, Frankel WL, Martin Eet al. Feasibility of screening for Lynch syndromeamong patients with colorectal cancer. J Clin Oncol 2008; 26: 5783–5788 [5] van Leerdam ME, Roos VH, van Hooft JE et al. Endoscopic manage- mentof polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2019; 51: 877–895 [6] Armelao F, de Pretis G. Familial

2020 European Society of Gastrointestinal Endoscopy

75. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT Full Text available with Trip Pro

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK 6 Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark 7 Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain 8 Australasian Gastro-Intestinal Trials Group, Camperdown, NSW, Australia 9 University of Uppsala, Uppsala, Sweden 10 Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK 11 Beatson

2020 NIHR HTA programme

76. Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Full Text available with Trip Pro

Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found that, for both cancers, whole-body MRI was as sensitive as standard staging. {{author}} {{($index , , , , , , , , , , , , , , , , & . Stuart A Taylor 1, * , Susan Mallett 2 , Anne Miles 3 , Stephen Morris 4 , Laura Quinn 2 , Caroline S Clarke 5 , Sandy Beare 6 , John Bridgewater 7 , Vicky Goh

2020 NIHR HTA programme

77. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

Sussex Hospitals NHS Foundation Trust, Chichester, UK. 6 Colorectal surgery, Raigmore Hospital, Inverness, UK. 7 Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK. 8 Histopathology, Nottingham University Hospitals, Nottingham, UK. 9 Family History of Bowel Cancer Clinic, West Middlesex University Hospital, London, UK. 10 Imperial College, London, UK. 11 Histopathology, University College London, London, UK. 12 Centre for Medical Imaging, UCL, London, UK. 13 Endoscopy, St Marks Hospital (...) Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE). They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 years and over. They are the first guidelines that take into account the introduction of national bowel cancer screening. For the first time, they also

2020 EvidenceUpdates

78. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates

79. Encorafenib (Braftovi) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation

Encorafenib (Braftovi) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation - Repository of AIHTA GmbH English | Browse - - - Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC (...) ) with a BRAF V600E mutation Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Oncology Fact Sheet Nr. 7. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 74kB Item Type: Oncology Fact Sheets Subjects: > > > > > Language: English Series Name: Oncology Fact Sheet Nr. 7 Deposited on: 02 Jun 2020 15:51 Last Modified: 15 Jul 2020 18:01 Repository

2020 Austrian Institute of Health Technology Assessment

80. Significance of epithelial-to-mesenchymal transition inducing transcription factors in predicting distance metastasis and survival in patients with colorectal cancer: A systematic review and meta-analysis Full Text available with Trip Pro

, Mosaad H, Abdelwahab MM, Abdelhamid MI, Mohamed SY, et al . Prognostic significance of the genetic and the immunohistochemical expression of epithelial-mesenchymal-related markers in colon cancer. Cancer Biomark 2017;20:107-22. Shen W, Cui L, Chen W. DKK4 is important in Snail1-induced chemoresistance to fluorouracilin colorectal cancer. Transl Cancer Res 2017;6:304-11. Wu DW, Lin PL, Cheng YW, Huang CC, Wang L, Lee H. DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β (...) expression in colon cancer cells. Gastroenterology 2011;141:2140-53. Busch EL, McGraw KA, Sandler RS. The potential for markers of epithelial-mesenchymal transition to improve colorectal cancer outcomes: A systematic review. Cancer Epidemiol Biomarkers Prev 2014;23:1164-75. Wan T, Zhang T, Si X, Zhou Y. Overexpression of EMT-inducing transcription factors as a potential poor prognostic factor for hepatocellular carcinoma in Asian populations: A meta-analysis. Oncotarget 2017;8:59500-8. Figures

2020 Journal of Research in Medical Sciences